Thermo Fisher Scientific Financial Statements (TMO)
|
|
|
|
Report date
|
|
|
24.02.2022 |
23.02.2023 |
22.02.2024 |
20.02.2025 |
26.02.2026 |
|
01.05.2026 |
|
Currency
|
|
|
USD |
USD |
USD |
USD |
USD |
|
USD |
|
Financial report URL
|
|
|
|
|
|
|
|
|
|
|
|
Revenue, bln rub |
? |
|
39 211 |
44 915 |
42 857 |
42 879 |
44 556 |
|
45 197 |
|
Operating Income, bln rub |
|
|
10 318 |
8 525 |
7 446 |
7 662 |
8 109 |
|
8 025 |
|
EBITDA, bln rub |
? |
|
11 969 |
11 942 |
11 195 |
11 800 |
11 466 |
|
11 161 |
|
Net profit, bln rub |
? |
|
7 725 |
6 950 |
5 995 |
6 335 |
6 737 |
|
6 859 |
|
|
OCF, bln rub |
? |
|
9 543 |
9 154 |
8 406 |
8 667 |
7 818 |
|
8 287 |
|
CAPEX, bln rub |
? |
|
2 523 |
2 243 |
1 479 |
1 400 |
1 525 |
|
1 539 |
|
FCF, bln rub |
? |
|
7 020 |
6 911 |
6 927 |
7 267 |
6 293 |
|
6 748 |
|
Dividend payout, bln rub
|
|
|
395.0 |
455.0 |
523.0 |
583.0 |
636.0 |
|
649.0 |
|
|
Ordinary share dividend yield, %
|
|
|
0.00% |
0.00% |
0.00% |
0.00% |
0.00% |
|
0.00% |
|
Dividend payout ratio, %
|
|
|
5.11% |
6.55% |
8.72% |
9.20% |
9.44% |
|
9.46% |
|
|
OPEX, bln rub |
|
|
9 316 |
10 486 |
9 748 |
10 066 |
8 669 |
|
9 790 |
|
Cost of production, bln rub |
|
|
19 577 |
25 904 |
25 663 |
25 151 |
27 778 |
|
27 385 |
|
R&D, bln rub |
|
|
1 406 |
1 471 |
1 337 |
1 390 |
1 397 |
|
1 392 |
|
Interest expenses, bln rub |
|
|
536.0 |
726.0 |
1 491 |
1 654 |
1 419 |
|
1 470 |
|
|
Assets, bln rub |
|
|
95 123 |
97 154 |
98 726 |
97 321 |
110 343 |
|
113 281 |
|
Net Assets, bln rub |
? |
|
40 793 |
43 978 |
46 735 |
49 584 |
53 407 |
|
51 940 |
|
Debt, bln rub |
|
|
36 339 |
36 073 |
36 424 |
32 775 |
40 855 |
|
43 161 |
|
Cash, bln rub |
|
|
4 477 |
8 524 |
8 083 |
5 580 |
10 110 |
|
3 256 |
|
Net debt, bln rub |
|
|
31 862 |
27 549 |
28 341 |
27 195 |
30 745 |
|
39 905 |
|
|
Ordinary share price, rub |
|
|
667.2 |
550.7 |
530.8 |
520.2 |
579.5 |
|
445.1 |
|
Number of ordinary shares, mln |
|
|
394.0 |
392.0 |
386.0 |
382.0 |
376.0 |
|
372.0 |
|
|
Market cap, bln rub |
|
|
262 893 |
215 870 |
204 885 |
198 728 |
217 873 |
|
165 566 |
|
EV, bln rub |
? |
|
294 755 |
243 419 |
233 226 |
225 923 |
248 618 |
|
205 471 |
|
Book value, bln rub |
|
|
-21 277 |
-14 696 |
-13 955 |
-11 802 |
-11 793 |
|
-22 393 |
|
|
EPS, rub |
? |
|
19.6 |
17.7 |
15.5 |
16.6 |
17.9 |
|
18.4 |
|
FCF/share, rub |
|
|
17.8 |
17.6 |
17.9 |
19.0 |
16.7 |
|
18.1 |
|
BV/share, rub |
|
|
-54.0 |
-37.5 |
-36.2 |
-30.9 |
-31.4 |
|
-60.2 |
|
|
EBITDA margin, % |
? |
|
30.5% |
26.6% |
26.1% |
27.5% |
25.7% |
|
24.7% |
|
Net margin, % |
? |
|
19.7% |
15.5% |
14.0% |
14.8% |
15.1% |
|
15.2% |
|
FCF yield, % |
? |
|
2.67% |
3.20% |
3.38% |
3.66% |
2.89% |
|
4.08% |
|
ROE, % |
? |
|
18.9% |
15.8% |
12.8% |
12.8% |
12.6% |
|
13.2% |
|
ROA, % |
? |
|
8.12% |
7.15% |
6.07% |
6.51% |
6.11% |
|
6.05% |
|
|
P/E |
? |
|
34.0 |
31.1 |
34.2 |
31.4 |
32.3 |
|
24.1 |
|
P/FCF |
|
|
37.4 |
31.2 |
29.6 |
27.3 |
34.6 |
|
24.5 |
|
P/S |
? |
|
6.70 |
4.81 |
4.78 |
4.63 |
4.89 |
|
3.66 |
|
P/BV |
? |
|
-12.4 |
-14.7 |
-14.7 |
-16.8 |
-18.5 |
|
-7.39 |
|
EV/EBITDA |
? |
|
24.6 |
20.4 |
20.8 |
19.1 |
21.7 |
|
18.4 |
|
Debt/EBITDA |
|
|
2.66 |
2.31 |
2.53 |
2.30 |
2.68 |
|
3.58 |
|
|
R&D/CAPEX, % |
|
|
55.7% |
65.6% |
90.4% |
99.3% |
91.6% |
|
90.4% |
|
|
CAPEX/Revenue, % |
|
|
6.43% |
4.99% |
3.45% |
3.27% |
3.42% |
|
3.41% |
|
| Thermo Fisher Scientific shareholders |
